Aurinia Publishes the Results of Lupkynis (voclosporin) in P-III AURORA 1 Study for Patients with Active Lupus Nephritis in The Lancet

 Aurinia Publishes the Results of Lupkynis (voclosporin) in P-III AURORA 1 Study for Patients with Active Lupus Nephritis in The Lancet

Shots:

  • The P-III AURORA 1 study involves assessing the efficacy and safety of Lupkynis (23.7mg, bid) + MMF and low-dose corticosteroids vs MMF and low-dose corticosteroids alone in 357 adults with SLE and LN
  • The trial met its 1EP and 2EPs i.e. complete renal response rates (41% vs 23%) @52wks. and 50% reduction from baseline in UPCR @24 & 52wks. and time to UPCR <0.5 mg/mg respectively. The therapy was well tolerated with no new safety signals
  • Lupkynis is the 1st FDA-approved oral therapy for LN. The company will share the longer-term safety and efficacy data from the ongoing AURORA 2 continuation study in the coming months

Click here to­ read full press release/ article | Ref: BUSINESS WIRE | Image: Crunchbase

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post